Argus notes that Emerson (EMR) shares have underperformed the broad market over the past three months, falling 14% while the S&P 500 declined 7%, despite the fact that Emerson reported fiscal Q1 EPS that rose 13% from a year earlier and exceeded analysts’ expectations. The firm, which is maintaining its Buy rating with a price target of $148, views the relative weakness in the shares as a buying opportunity, the analyst tells investors. Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on EMR: Disclaimer & DisclosureReport an Issue